TL;DR — Key Procurement Insights for Australian Distributors (6‑in‑1 Respiratory Combo)
The Flu A/B + COVID‑19/HMPV+RSV/Adeno Antigen Combo Test Cassette (Nasal Swab) delivers results for six respiratory viruses from a single nasal swab in 10 minutes. The COVID‑19 test line uses nucleocapsid protein detection; Flu A and Flu B lines use nucleoprotein detection; RSV uses fusion protein detection; HMPV and Adenovirus use specific antibody detection. Each test line has its own procedural control.
This product has received TGA (Therapeutic Goods Administration) approval for self‑testing in Australia, classified as Class 3 IVD. Manufacturers must submit clinical performance data for each target as part of the conformity assessment.
Under Australia’s Community Pharmacy Agreement, accredited pharmacists can perform rapid antigen tests and dispense antiviral treatments under the PBS – creating a formal revenue pathway for pharmacy procurement of multi‑target test kits.
During the 2026 winter season (May to September) , Australian pharmacy chains and public health distributors are expected to drive strong seasonal demand for 6‑in‑1 respiratory combo cassettes, as the peaks of influenza, COVID‑19, RSV, HMPV and adenovirus overlap – making pharmacy‑based point‑of‑care testing a procurement priority.
How Australian Pharmacies Cut Testing Time to 10 Minutes with a 6‑in‑1 Respiratory Combo Cassette
The Respiratory Testing Gap That Australian Pharmacies Are Filling
Working in the IVD industry for over a decade, I have watched the Australian market for point‑of‑care respiratory testing transform faster than almost any other developed market. The trigger was not new technology – it was a reimbursement reform.
Australia’s Community Pharmacy Agreement (the 7th Agreement came into effect in 2025) expanded the scope of pharmacist‑administered services to include point‑of‑care testing for respiratory infections. Under this framework, an accredited community pharmacist can perform a rapid antigen test, interpret the result, and if positive for influenza, dispense an antiviral medication under the Pharmaceutical Benefits Scheme (PBS). The patient leaves the pharmacy with a confirmed diagnosis and a prescription filled in the same visit, typically within 20 minutes.
This clinical pathway creates a procurement requirement that did not exist five years ago: pharmacy chains need reliable, multi‑target rapid test cassettes that can differentiate between influenza A, influenza B, COVID‑19, human metapneumovirus (HMPV), respiratory syncytial virus (RSV), and adenovirus from a single nasal swab, deliver results within 10 minutes, and meet the TGA’s performance standards for self‑testing.
In this guide, I walk through the technical specifications, regulatory requirements, and procurement considerations for the TGA‑certified Flu A/B + COVID‑19/HMPV+RSV/Adeno Antigen Combo Test Cassette, drawing on Testsealabs’ experience supplying IVD products to over 100 countries globally.
What the 6‑in‑1 Combo Cassette Detects and How It Works
The lateral flow immunoassay format is well established, but the 6‑in‑1 combo cassette presents a significant engineering challenge: six distinct test lines (Flu A, Flu B, COVID‑19, HMPV, RSV, Adenovirus) plus a procedural control line must be integrated on a single nitrocellulose membrane strip while maintaining specificity and preventing cross‑reactivity between the six targets.
Target Antigens and Detection Mechanism (based on the product IFU)
- COVID‑19 line – uses monoclonal antibodies specific to the SARS‑CoV‑2 nucleocapsid (N) protein.
- Flu A and Flu B lines – use antibodies targeting the viral nucleoprotein, which is highly conserved across circulating influenza strains.
- RSV line – targets the fusion (F) protein.
- HMPV and Adenovirus lines – use their respective specific antibodies.
Each test line includes a capture and detection antibody system. The procedural control line contains goat anti‑mouse IgG antibody to capture excess antibody conjugate, confirming that the test ran correctly regardless of the sample type.
Sample Collection and Processing
The test uses a single nasopharyngeal or anterior nasal swab collected according to standard clinical practice. After collection, the swab is inserted into the extraction buffer tube and rotated 10‑15 times to transfer viral particles into the liquid phase. Three to four drops of the extracted sample are dispensed into the cassette’s sample well. The lateral flow membrane draws the sample through the conjugate pad – where gold nanoparticle‑antibody conjugates bind to any viral antigens present – and across the six test lines and the control line. The entire process from sample well loading to readable result takes 10 minutes, with no instrumentation required beyond the cassette itself.
TGA Regulatory Pathway and Certification Status
This product has obtained TGA certification for self‑testing in Australia. The TGA classifies IVD medical devices under a four‑class system. The Flu A/B + COVID‑19/HMPV+RSV/Adeno Antigen Combo Test Cassette (Nasal Swab) is classified as Class 3 IVD under the Therapeutic Goods (Medical Devices) Regulations 2002.
The regulatory pathway requires the manufacturer to submit a comprehensive application including clinical performance data for each target, analytical specificity studies, manufacturing quality system documentation (ISO 13485), and a Declaration of Conformity.
Clinical Performance Requirements (general statement)
The TGA requires clinical performance data demonstrating diagnostic sensitivity and specificity for each target separately. The manufacturer has submitted such data for all six targets (Flu A, Flu B, COVID‑19, HMPV, RSV, Adenovirus). The product meets the TGA’s performance expectations for a Class 3 self‑testing IVD.
Important limitations (based on the IFU)
- Multiplex design inherently has a trade‑off – sensitivity for each individual target is slightly lower than that of a single‑target cassette. For pharmacy‑based screening (where the alternative is no test at all), this is acceptable.
- A negative result may occur if the antigen level in a sample is below the detection limit.
- Positive results do not rule out co‑infections with other pathogens, nor do they differentiate between SARS‑CoV and COVID‑19 antigen.
- If symptoms have been present for more than seven days, a negative result should be treated as presumptive – confirmation with a molecular assay may be required if clinically indicated.
Australian Market Logistics for Diagnostic Products
Cold Chain Requirements
Although lateral flow immunoassays are more temperature‑tolerant than molecular diagnostics, the recommended storage temperature for this combo cassette is 4‑30°C. Shipments to Australia during the Australian summer (December‑February, when containers crossing the equator can experience internal temperatures exceeding 50°C) require refrigerated container (reefer) shipping or temperature‑controlled packaging. The standard 20‑foot reefer container surcharge from Shanghai or Shenzhen to Sydney or Melbourne adds approximately USD 1,200‑2,200 per shipment over dry container rates.
Customs Clearance Documentation for TGA‑Listed Devices
The Australian Border Force and the Department of Agriculture require specific documentation for IVD imports: the ARTG listing number, the manufacturer’s ISO 13485 certificate, the Certificate of Free Sale (or equivalent), and a commercial invoice listing the product’s GMDN code. Shipments without complete documentation are subject to quarantine hold at the border, with storage fees accruing at approximately USD 50‑150 per day. Testsealabs provides a complete customs clearance documentation package with every export shipment.
Procurement Considerations for Pharmacy Chains and Public Health Distributors
Volume Commitments and Seasonal Demand Forecasting
The Australian winter respiratory season runs from May through September, with overlapping peaks of influenza, COVID‑19, RSV, HMPV and adenovirus. For a pharmacy chain ordering 200,000‑500,000 units per season, Testsealabs recommends a two‑stage ordering approach:
- 60% of the anticipated seasonal volume placed by March (for June arrival)
- 40% placed by May (for August arrival)
A 10‑15% volume flexibility clause in the supply agreement is recommended to adjust upward if the season is more severe than forecast.
Kit Configuration Options for the Australian Market
Testsealabs offers the 6‑in‑1 combo cassette in two configurations:
- Standard configuration – 25 tests per kit box, each test individually pouched in foil packaging with desiccant.
- Bulk configuration – 100 tests per kit, pouched tests packed in a larger outer carton without individual kit boxes – reducing packaging waste and per‑test cost by approximately 5‑8%.
Both configurations include extraction buffer, swabs, and the package insert in English, compliant with TGA labelling requirements.
Frequently Asked Questions
Q1: What is the minimum order quantity (MOQ) for this 6‑in‑1 combo cassette?
A: The standard MOQ is 5,000 test kits per order, with a single PO covering one configuration (either 25‑test or 100‑test format). For OEM custom packaging (pharmacy chain’s own brand, custom instruction leaflet, Australian market‑specific labelling), the MOQ is 50,000 test kits per SKU per design. OEM custom packaging adds 4‑6 weeks to the standard production lead time due to artwork approval, printing, and packaging material procurement.
Q2: Does the test differentiate between Flu A and Flu B, or just report influenza positive/negative?
A: It differentiates with separate test lines. Result interpretation:
- Flu A positive – control line + Flu A line appear.
- Flu B positive – control line + Flu B line appear.
- Both Flu A and B positive – control line + both influenza lines appear.
COVID‑19, HMPV, RSV and Adenovirus lines are independent – a sample can be positive for multiple viruses simultaneously (co‑infection is clinically documented). Differentiation is important for antiviral prescribing because the PBS streamlined pathway requires a confirmed influenza diagnosis.
Q3: What is the shelf life and storage condition?
A: 24 months from the date of manufacture when stored in the sealed foil pouch at 4‑30°C. The product does not require freezing. Once the foil pouch is opened, the test must be used within 60 minutes. Testsealabs ships test kits with a minimum of 15 months remaining shelf life upon arrival at the Australian port.
Q4: Can the test be used for paediatric respiratory infection diagnosis?
A: According to the IFU, the test is validated for use in children over 2 years of age. It should not be performed on children under 2 years. Persons under 18 years require adult supervision or assistance. RSV, HMPV and adenovirus are particularly relevant for paediatric populations – RSV is the leading cause of bronchiolitis hospitalisation in children under 2 years in Australia. The combo test allows a pharmacist or nurse to differentiate between RSV/HMPV/adenovirus infection (supportive care) and influenza (antiviral treatment) in a paediatric outpatient setting.
Q5: What is the readout time – 15 minutes or 10 minutes?
A: According to the product IFU, the readout time for this 6‑in‑1 combo cassette is 10 minutes.
Q6: Is the product TGA‑certified?
A: Yes. The Flu A/B + COVID‑19/HMPV+RSV/Adeno Antigen Combo Test Cassette (Nasal Swab) has obtained TGA certification as a Class 3 IVD for self‑testing and is listed on the ARTG. Customers can request a copy of the TGA certificate.
Q7: What should a patient do if the COVID‑19 test is positive?
A: As stated in the IFU precautions:
- Stay home to protect others in the community.
- Do not go to hospitals or high‑risk places such as nursing homes for the elderly or people with disabilities.
- If you feel unwell or need advice, contact your healthcare provider or call the Health Direct helpline 1800 022 22 to speak to a nurse.
- In case of severe dyspnoea or chest pain, immediately call 000.
Q8: What is the typical lead time for an order destined for Australian pharmacies?
A: For standard Testsealabs brand packaging (5,000‑50,000 test kits):
- Production lead time: 25‑30 working days after confirmed order and deposit.
- Sea freight (Shanghai to Sydney): 18‑22 days transit.
- Total lead time to Australian port: 45‑55 working days (9‑11 calendar weeks).
For OEM custom packaging: add 4‑6 weeks for packaging development.
For urgent orders during peak respiratory season, air freight is available with total lead time of 15‑20 working days, provided the order volume is a minimum of USD 50,000 or 25,000 test kits in standard packaging.
About the Author
Angela Qin – International Sales Director, Hangzhou Testsea Biotechnology Co., Ltd. (Testsealabs)
Angela Qin is the International Sales Director at Hangzhou Testsea Biotechnology Co., Ltd. (Testsealabs), with 10+ years of experience in the in vitro diagnostic (IVD) and veterinary product industry. Founded in 2015 with the pursuit “serving society, health world,” Testsealabs specialises in the R&D, production, and sales of rapid diagnostic products, including tests for coronavirus disease, cardiovascular diseases, inflammation, tumour markers, infectious diseases, drug abuse, and pregnancy. Leveraging proprietary platforms (immunological detection, molecular biology, protein chip, and biological raw materials), Angela helps global distributors, hospitals, public health institutions, and veterinary clients source reliable, high‑quality diagnostic solutions from China – backed by strict quality control and a customer‑first philosophy. Testsealabs’ products are widely used in rapid diagnosis, treatment monitoring, maternal and child healthcare, drug and alcohol testing, and have been sold to over 100 countries worldwide.
Facebook: Testsealabs Facebook
LinkedIn: Testsealabs LinkedIn
Post time: Jun-16-2026